Jonathan Aschoff
Stock Analyst at Roth Capital
(0.52)
# 4,144
Out of 5,176 analysts
39
Total ratings
26.19%
Success rate
-38.42%
Average return
Main Sectors:
Stocks Rated by Jonathan Aschoff
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PTHS Pelthos Therapeutics | Maintains: Buy | $57 → $55 | $22.09 | +148.98% | 2 | Feb 26, 2026 | |
| GTBP GT Biopharma | Initiates: Buy | $11 | $0.47 | +2,265.59% | 1 | Dec 2, 2024 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $19 → $21 | $9.13 | +130.01% | 2 | Sep 24, 2024 | |
| APVO Aptevo Therapeutics | Maintains: Buy | $199,800 → $106,560 | $4.43 | +2,408,035.59% | 3 | Sep 23, 2024 | |
| BRTX BioRestorative Therapies | Maintains: Buy | $15 → $18 | $0.31 | +5,706.45% | 4 | Aug 14, 2024 | |
| NUWE Nuwellis | Reiterates: Buy | $714 | $1.15 | +61,986.96% | 2 | Aug 13, 2024 | |
| GOVX GeoVax Labs | Initiates: Buy | $500 | $1.50 | +33,233.33% | 1 | Jul 16, 2024 | |
| MBRX Moleculin Biotech | Maintains: Buy | $1,000 | $2.49 | +40,060.64% | 2 | Apr 12, 2024 | |
| CLRB Cellectar Biosciences | Maintains: Buy | $600 → $840 | $2.95 | +28,374.58% | 4 | Mar 28, 2024 | |
| HSDT Solana Company | Maintains: Buy | $3,750 → $18,000 | $2.16 | +833,233.33% | 2 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $14.00 | +114.29% | 3 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $200 | $5.48 | +3,549.64% | 1 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $14 | $8.91 | +57.13% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28,800 → $86,400 | $1.18 | +7,321,933.90% | 2 | Feb 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $8 | $1.95 | +310.26% | 1 | Jun 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $100 | $1.87 | +5,247.59% | 1 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $400 | $0.82 | +48,913.60% | 1 | Nov 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $38 | $6.91 | +449.93% | 1 | Mar 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $96 | $1.54 | +6,133.77% | 3 | Nov 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $1.22 | +965.57% | 1 | Dec 19, 2019 |
Pelthos Therapeutics
Feb 26, 2026
Maintains: Buy
Price Target: $57 → $55
Current: $22.09
Upside: +148.98%
GT Biopharma
Dec 2, 2024
Initiates: Buy
Price Target: $11
Current: $0.47
Upside: +2,265.59%
Zevra Therapeutics
Sep 24, 2024
Maintains: Buy
Price Target: $19 → $21
Current: $9.13
Upside: +130.01%
Aptevo Therapeutics
Sep 23, 2024
Maintains: Buy
Price Target: $199,800 → $106,560
Current: $4.43
Upside: +2,408,035.59%
BioRestorative Therapies
Aug 14, 2024
Maintains: Buy
Price Target: $15 → $18
Current: $0.31
Upside: +5,706.45%
Nuwellis
Aug 13, 2024
Reiterates: Buy
Price Target: $714
Current: $1.15
Upside: +61,986.96%
GeoVax Labs
Jul 16, 2024
Initiates: Buy
Price Target: $500
Current: $1.50
Upside: +33,233.33%
Moleculin Biotech
Apr 12, 2024
Maintains: Buy
Price Target: $1,000
Current: $2.49
Upside: +40,060.64%
Cellectar Biosciences
Mar 28, 2024
Maintains: Buy
Price Target: $600 → $840
Current: $2.95
Upside: +28,374.58%
Solana Company
Mar 5, 2024
Maintains: Buy
Price Target: $3,750 → $18,000
Current: $2.16
Upside: +833,233.33%
Feb 20, 2024
Reiterates: Buy
Price Target: $30
Current: $14.00
Upside: +114.29%
Aug 29, 2023
Reiterates: Buy
Price Target: $200
Current: $5.48
Upside: +3,549.64%
Aug 14, 2023
Reiterates: Buy
Price Target: $14
Current: $8.91
Upside: +57.13%
Feb 14, 2023
Maintains: Buy
Price Target: $28,800 → $86,400
Current: $1.18
Upside: +7,321,933.90%
Jun 15, 2022
Reinstates: Buy
Price Target: $8
Current: $1.95
Upside: +310.26%
Feb 25, 2022
Initiates: Buy
Price Target: $100
Current: $1.87
Upside: +5,247.59%
Nov 24, 2021
Initiates: Buy
Price Target: $400
Current: $0.82
Upside: +48,913.60%
Mar 11, 2021
Initiates: Buy
Price Target: $38
Current: $6.91
Upside: +449.93%
Nov 17, 2020
Downgrades: Sell
Price Target: $96
Current: $1.54
Upside: +6,133.77%
Dec 19, 2019
Initiates: Buy
Price Target: $13
Current: $1.22
Upside: +965.57%